Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response

Eric Huang, Malgorzata Maciukiewicz, Clement C. Zai, Arun K. Tiwari, Jiang Li, Steven G. Potkin, Jeffrey A. Lieberman, Herbert Y. Meltzer, Daniel J. Müller, James L. Kennedy*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Aim: The recent Psychiatric Genomics Consortium genome-wide association study identified an SNP, rs2514218, located 47kb upstream of the DRD2 gene to be associated with risk for schizophrenia (p = 2.75e-11). Since all antipsychotics bind to dopamine D2 receptors, we examined rs2514218 in relation to response to antipsychotic treatment. Patients & methods: We investigated the SNP in relation to treatment response in a prospective study consisting of 208 patients (151 Caucasians, 42 African-Americans and 15 others) treated with clozapine for 6 months. Results: rs2514218 was associated with total score change in the brief psychiatric rating scale under an additive model (pcorr= 0.033). Conclusion: Our finding provides evidence for rs2514218 association with antipsychotic response, but further replication is required before firm conclusions can be drawn.

Original languageEnglish (US)
Pages (from-to)103-109
Number of pages7
JournalPharmacogenomics
Volume17
Issue number2
DOIs
StatePublished - Jan 2016

Keywords

  • antipsychotic
  • clinical response
  • clozapine
  • dopamine D2 receptor
  • genetics
  • pharmacogenetics
  • schizophrenia

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Fingerprint Dive into the research topics of 'Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response'. Together they form a unique fingerprint.

Cite this